Research Associate
Laboratory for Molecular Biomedicine

Institute of Molecular Genetics and Genetic Engineering (IMGGE),
University of Belgrade (UB)

Vojvode Stepe 444a, PO box 23, 11010 Belgrade, Serbia
Mobile:    +381 65 397 64 45                            
Phone:    +381 11 397 64 45
Fax:        +381 11 397 58 08
E-mail: nikola.kotur@imgge.bg.ac.rs

EDUCATION

2015 - PhD in Molecular Biology, Faculty of Biology (FB), University of Belgrade (UB) (Thesis: Pharmacogenetics of 6-mercaptopurine and methotrexate in childhood acute lymphoblastic leukemia)
2009 - Diploma (equivalent to M.Sc.) in Molecular biology and physiology, FB, UB

RESEARCH EXPERIENCE

2015 - Research Associate at Laboratory for Molecular Biomedicine, IMGGE
2012 - Research Assistant at Laboratory for Molecular Biomedicine, IMGGE
2011 - Research Trainee at Laboratory for Molecular Hematology, IMGGE

RESEARCH INTEREST

The focus of my research is pharmacogenetics of acute lymphoblastic leukaemia (ALL) in children. Backbone therapy for these patients consists of methotrexate and 6-mercaptopurine (6-MP) drugs, whose efficacy and toxicity is dependent on genetic variants in genes encoding enzymes and transporters in metabolic pathways of these drugs. The aim is to find genetic variants that influence therapy related toxicity in ALL patients in order to personalize therapy dosage according to genetic signature of a patient.

Thiopurine S-methyltransferase (TPMT) is a 6-MP clearing enzyme. The goal is to explain influence of 6-MP drug in context of architecture of VNTR region in TPMT promoter on transcription of TPMT gene. Better understanding of TPMT transcription will contribute to 6-MP therapy improvement toward safety and efficacy.

SELECTED PUBLICATIONS

[1] N. Kotur, L. Dokmanovic, D. Janic, B. Stankovic, N. Krstovski, N. Tosic, T. Katsila, G. P. Patrinos, B. Zukic, and S. Pavlovic, “TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.,” Pharmacogenomics, vol. 16, no. 15, pp. 1701–12, Oct. 2015.

[2] N. Kotur, B. Stankovic, K. Kassela, M. Georgitsi, A. Vicha, I. Leontari, L. Dokmanovic, D. Janic, N. Krstovski, K. Klaassen, M. Radmilovic, M. Stojiljkovic, G. Nikcevic, A. Simeonidis, G. Sivolapenko, S. Pavlovic, G. P. Patrinos, and B. Zukic, “6-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner.,” Pharmacogenomics, vol. 13, no. 3, pp. 283–95, Feb. 2012.

[3]M. Radmilovic, B. Zukic, M. S. Petrovic, M. Bartsakoulia, B. Stankovic, N. Kotur, L. Dokmanovic, M. Georgitsi, G. P. Patrinos, and S. Pavlovic, “Functional analysis of a novel KLF1 gene promoter variation associated with hereditary persistence of fetal hemoglobin.,” Ann. Hematol., vol. 92, no. 1, pp. 53–8, Jan. 2013.

[4] K. Klaassen, B. Stankovic, N. Kotur, M. Djordjevic, B. Zukic, G. Nikcevic, M. Ugrin, V. Spasovski, S. Srzentic, S. Pavlovic, and M. Stojiljkovic, “New PAH gene promoter KLF1 and 3’-region C/EBPalpha motifs influence transcription in vitro.,” J. Appl. Genet., Jul. 2016.

[5] B. Stankovic, S. Dragasevic, D. Popovic, B. Zukic, N. Kotur, A. Sokic-Milutinovic, T. Alempijevic, S. Lukic, T. Milosavljevic, G. Nikcevic, and S. Pavlovic, “Variations in inflammatory genes as molecular markers for prediction of inflammatory bowel disease occurrence.,” J. Dig. Dis., vol. 16, no. 12, pp. 723–33, Dec. 2015.

[6] A. Z. Alimpic, N. Kotur, B. Stanković, P. D. Marin, V. Matevski, N. Al Sheef, and S. Duletić-Laušević, “The  in vitro  antioxidative and cytotoxic effects of selected  Salvia  species water extracts,” Journal of Applied Botany and Food Quality, vol. 88, no. 1. 05-May-2015.

[7] I. Jančić, M. Šefik-Bukilica, S. Živojinović, N. Damjanov, V. Spasovski, N. Kotur, K. Klaassen, S. Pavlović, B. Bufan, and N. Arsenović-Ranin, “Influence of Promoter Polymorphisms of the TNF-α (-308G/A) And IL-6 (-174G/C) Genes On Therapeutic Response To Etanercept In Rheumatoid Arthritis,” J. Med. Biochem., pp. 1–8, Jan. 2015.

[8] B. Stanković, N. Radlović, Z. Leković, D. Ristić, V. Radlović, G. Nikčević, N. Kotur, K. Vučićević, T. Kostić, S. Pavlović, and B. Zukic, “HLA genotyping in pediatric celiac disease patients.,” Bosn. J. Basic Med. Sci., vol. 14, no. 3, pp. 171–6, Jan. 2014.